To view this email as a web page, go to the link below, or copy and paste it into your browser's address window.
[link removed]
Having trouble viewing this email?
[link removed]
View online
The U.S. Can Lower Drug Prices Without Sacrificing Innovation
October 4, 2021
[link removed]
[link removed]
[link removed]
With Congress considering legislation to allow Medicare to use its bargaining power to negotiate lower drug prices, large pharmaceutical companies are once again arguing that proposed price controls will stifle long-term innovation in drug development.
In an op-ed in Harvard Business Review, the Commonwealth Fund’s David Blumenthal, M.D., and Lovisa Gustafsson join Arnold Ventures’ Mark E. Miller in explaining why that claim is untrue. In fact, they say, big pharmaceutical companies are no longer the dominant sources of biomedical innovation. Instead, truly innovative therapies now originate from small university research spinoffs, mostly funded by the National Institutes of Health (NIH) and philanthropy.
The key to supporting drug innovation, the authors say, is to increase NIH funding, reduce the cost and increase the speed of clinical trials, and reform patent law.
[link removed]
Read more
Affordable, quality health care. For everyone.
[link removed]
Manage Profile |
[link removed]
Manage Subscriptions |
[link removed]
Privacy policy |
[link removed]
Unsubscribe
Add
mailto:
[email protected]?omnicid=CFC2029752&
[email protected]
[email protected] to your address book [
[link removed]
vCard ]
2021 (c) The Commonwealth Fund
THE COMMONWEALTH FUND | One E 75th St, New York, NY 10021 United States | Phone: 212.606.3800
----------------------------------------
This email was sent by:
THE COMMONWEALTH FUND
One E 75th St
New York, NY, 10021, United States
We respect your right to privacy - visit the following URL to view our policy.
( [link removed] )
----------------------------------------
Visit the following URL to manage your subscriptions.
( [link removed] )
Visit the following URL to update your profile.
( [link removed] )
Visit the following URL to unsubscribe.
( [link removed] )
